AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12755526 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol target controlled infusion at 4 mcg/mL
Number of subjects: 69
Study 12755526 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol target controlled infusion at 5 mcg/mL
Number of subjects: 69
Study 12755526 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol target controlled infusion at 6 mcg/mL
Number of subjects: 69
Study 11184063 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary therapy candidates according to NCEP II guidelines
Number of subjects: 2078
Study 11184063 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary therapy candidates according to European guidelines
Number of subjects: 2078
Study 11184063 — intervention group
Group type: EXPERIMENTAL
Intervention: Antilipemic drug therapy candidates according to NCEP II guidelines
Number of subjects: 2078
Study 11184063 — intervention group
Group type: EXPERIMENTAL
Intervention: Antilipemic drug therapy candidates according to European guidelines
Number of subjects: 2078
Study 11184063 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary therapy received by diagnosed dietary therapy candidates according to NCEP II guidelines
Number of subjects: 2078
Study 11184063 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary therapy received by diagnosed dietary therapy candidates according to European guidelines
Number of subjects: 2078
Study 11184063 — intervention group
Group type: EXPERIMENTAL
Intervention: Antilipemic drug therapy received by diagnosed drug therapy candidates according to NCEP II guidelines
Number of subjects: 2078
Study 11184063 — intervention group
Group type: EXPERIMENTAL
Intervention: Antilipemic drug therapy received by diagnosed drug therapy candidates according to European guidelines
Number of subjects: 2078
Study 11184063 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis of high blood cholesterol levels among NCEP II drug therapy candidates
Number of subjects: 2078
Study 11184063 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis of high blood cholesterol levels among European drug therapy candidates
Number of subjects: 2078
Study 8783307 — intervention group
Group type: EXPERIMENTAL
Intervention: Coloured Analogue Scale (CAS)
Number of subjects: 104
Study 8783307 — intervention group
Group type: COMPARATOR
Intervention: Visual Analogue Scale (VAS)
Number of subjects: 104
Study 8270437 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy plus hyperthermia
Number of subjects: 41
Study 8270437 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy alone
Number of subjects: 41
Study 3370412 — intervention group
Group type: EXPERIMENTAL
Intervention: Iothalamate
Number of subjects: 45
Study 3370412 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopamidol
Number of subjects: 45
Study 3370412 — intervention group
Group type: EXPERIMENTAL
Intervention: Ioxaglate
Number of subjects: 45
Study 3370412 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific control mentioned)
Number of subjects: 45
Study 31586600 — intervention group
Group type: EXPERIMENTAL
Intervention: SB206 4% twice daily
Number of subjects: 256
Study 31586600 — intervention group
Group type: EXPERIMENTAL
Intervention: SB206 8% twice daily
Number of subjects: 256
Study 31586600 — intervention group
Group type: EXPERIMENTAL
Intervention: SB206 12% twice daily
Number of subjects: 256
Study 31586600 — intervention group
Group type: EXPERIMENTAL
Intervention: SB206 12% once daily
Number of subjects: 256
Study 31586600 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 256
Study 31586600 — intervention group
Group type: EXPERIMENTAL
Intervention: SB206 (all doses)
Number of subjects: 256
Study 31586600 — intervention group
Group type: EXPERIMENTAL
Intervention: SB206 4%, 8%, and 12% twice daily
Number of subjects: 256
Study 30630791 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group (exposed to clopidogrel and aspirin)
Number of subjects: 180
Study 30630791 — intervention group
Group type: COMPARATOR
Intervention: Control group (not exposed to clopidogrel and aspirin)
Number of subjects: 180
Study 26952245 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine
Number of subjects: 6491
Study 26952245 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6491
Study 26073395 — intervention group
Group type: COMPARATOR
Intervention: 0 g/d EPA + DHA (placebo)
Number of subjects: 25
Study 26073395 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.85 g/d EPA + DHA (low dose)
Number of subjects: 25
Study 26073395 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.4 g/d EPA + DHA (high dose)
Number of subjects: 25
Study 23750465 — intervention group
Group type: EXPERIMENTAL
Intervention: High treatment dose (high attendance, exposure completion)
Number of subjects: 439
Study 23750465 — intervention group
Group type: EXPERIMENTAL
Intervention: High patient engagement (homework adherence, commitment)
Number of subjects: 439
Study 23750465 — intervention group
Group type: COMPARATOR
Intervention: Low treatment dose (low attendance, exposure completion)
Number of subjects: 439
Study 23750465 — intervention group
Group type: COMPARATOR
Intervention: Low patient engagement (low homework adherence, commitment)
Number of subjects: 439
Study 21445641 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous selenite as a bolus-loading dose of 2,000 μg Se followed by continuous infusion of 1,600 μg Se per day for 10 days
Number of subjects: 35
Study 21445641 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous selenite
Number of subjects: 35
Study 18279770 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan (not specified dosage or duration)
Number of subjects: 4133
Study 18279770 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4133
Study 17097993 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone (prescribed for at least 30 days before transplantation)
Number of subjects: 396
Study 17097993 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients not prescribed amiodarone)
Number of subjects: 396
Study 14586350 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol 25 mug every 3 hours
Number of subjects: 146
Study 14586350 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracervical 16F Foley catheter
Number of subjects: 146
Study 14586350 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination misoprostol-Foley catheter
Number of subjects: 146
Study 14586350 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 146
Study 10722450 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 575
Study 10722450 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal zanamivir
Number of subjects: 575
Study 10722450 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled zanamivir
Number of subjects: 575
Study 10722450 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled plus intranasal zanamivir
Number of subjects: 575
Study 7788012 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH (1 microgram/kg iv 2 h before tests)
Number of subjects: 53
Study 7788012 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin hypoglycemia
Number of subjects: 53
Study 7788012 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 53
Study 7788012 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine
Number of subjects: 53
Study 7788012 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH, Insulin, Clonidine
Number of subjects: 53
Study 1973202 — intervention group
Group type: EXPERIMENTAL
Intervention: Sydnocarb
Number of subjects: 21
Study 1973202 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 517586 — intervention group
Group type: EXPERIMENTAL
Intervention: 2,000 U heparin/12 hr subcutaneously
Number of subjects: 75
Study 517586 — intervention group
Group type: EXPERIMENTAL
Intervention: 5,000 U heparin/12 hr subcutaneously
Number of subjects: 75
Study 517586 — intervention group
Group type: COMPARATOR
Intervention: Control group (no heparin)
Number of subjects: 75
Study 31010891 — intervention group
Group type: EXPERIMENTAL
Intervention: Lean methods applied to CAD/CAM education
Number of subjects: 66
Study 31010891 — intervention group
Group type: COMPARATOR
Intervention: Existing teaching methods (Control)
Number of subjects: 66
Study 25890673 — intervention group
Group type: EXPERIMENTAL
Intervention: E/C/F/tenofovir alafenamide
Number of subjects: 1733
Study 25890673 — intervention group
Group type: COMPARATOR
Intervention: E/C/F/tenofovir disoproxil fumarate
Number of subjects: 1733
Study 23527645 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular prospective memory tasks with less focal cues
Number of subjects: 52
Study 23527645 — intervention group
Group type: EXPERIMENTAL
Intervention: Irregular prospective memory tasks
Number of subjects: 52
Study 23527645 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrospective memory for irregular tasks
Number of subjects: 52
Study 23527645 — intervention group
Group type: EXPERIMENTAL
Intervention: Cues that reduce executive control demands
Number of subjects: 52
Study 23527645 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased retrospective memory demand
Number of subjects: 52
Study 21451098 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-day university course for physical therapists
Number of subjects: 42
Study 21451098 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (control group)
Number of subjects: 42
Study 19859531 — intervention group
Group type: COMPARATOR
Intervention: sdNVP alone
Number of subjects: 406
Study 19859531 — intervention group
Group type: EXPERIMENTAL
Intervention: NVP/CBV4 (sdNVP with AZT plus 3TC for 4 days)
Number of subjects: 406
Study 19859531 — intervention group
Group type: EXPERIMENTAL
Intervention: NVP/CBV7 (sdNVP with AZT plus 3TC for 7 days)
Number of subjects: 406
Study 19859531 — intervention group
Group type: EXPERIMENTAL
Intervention: NVP/CBV4 and NVP/CBV7 combined
Number of subjects: 406
Study 16507190 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.015 mg morphine (Group I, n=25)
Number of subjects: 144
Study 16507190 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.03 mg morphine (Group II, n=30)
Number of subjects: 144
Study 16507190 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.06 mg morphine (Group III, n=31)
Number of subjects: 144
Study 16507190 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg morphine (Group IV, n=33)
Number of subjects: 144
Study 16507190 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control group, n=25)
Number of subjects: 144
Study 16507190 — intervention group
Group type: EXPERIMENTAL
Intervention: All morphine groups
Number of subjects: 144
Study 14967752 — intervention group
Group type: EXPERIMENTAL
Intervention: Easy breath-hold instruction
Number of subjects: 150
Study 14967752 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhale/easy breath-hold instruction
Number of subjects: 150
Study 14967752 — intervention group
Group type: EXPERIMENTAL
Intervention: Hard breath-hold instruction
Number of subjects: 150
Study 11354530 — intervention group
Group type: EXPERIMENTAL
Intervention: Nephron-sparing surgery (NSS)
Number of subjects: 0
Study 11354530 — intervention group
Group type: COMPARATOR
Intervention: Radical nephrectomy
Number of subjects: 0
Study 9480239 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-pregnant women with RSA
Number of subjects: 117
Study 9480239 — intervention group
Group type: COMPARATOR
Intervention: Healthy non-pregnant multigravidas (control)
Number of subjects: 117
Study 7695707 — intervention group
Group type: EXPERIMENTAL
Intervention: Plantar strike technique
Number of subjects: 12
Study 7695707 — intervention group
Group type: COMPARATOR
Intervention: Tendon strike technique
Number of subjects: 12
Study 2902264 — intervention group
Group type: EXPERIMENTAL
Intervention: Edmonston-Zagreb (EZ) measles vaccine, 40,000 PFU at 4 months of age
Number of subjects: 239
Study 2902264 — intervention group
Group type: COMPARATOR
Intervention: Schwarz measles vaccine, 6000 TCID50 at 9 months of age
Number of subjects: 239
Study 2902264 — intervention group
Group type: EXPERIMENTAL
Intervention: EZ vaccine
Number of subjects: 239
Study 2902264 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 239
Study 31840247 — intervention group
Group type: EXPERIMENTAL
Intervention: High-definition transcranial direct current stimulation (HD-tDCS) of the left dorsolateral prefrontal cortex (DLPFC)
Number of subjects: 27
Study 31840247 — intervention group
Group type: EXPERIMENTAL
Intervention: High-definition transcranial direct current stimulation (HD-tDCS) of the right dorsolateral prefrontal cortex (DLPFC)
Number of subjects: 27
Study 31840247 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 27
Study 31230384 — intervention group
Group type: EXPERIMENTAL
Intervention: Organ Care System (OCS)
Number of subjects: 39
Study 31230384 — intervention group
Group type: COMPARATOR
Intervention: Cold Storage (CS)
Number of subjects: 39
Study 28664912 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined biomarker panel (IGFBP2, LCAT, CA125)
Number of subjects: 80
Study 28664912 — intervention group
Group type: COMPARATOR
Intervention: CA125 alone
Number of subjects: 80
Study 25923481 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein diet (protein enriched bread and protein enriched drinking yoghurt; n=17)
Number of subjects: 34
Study 25923481 — intervention group
Group type: COMPARATOR
Intervention: Regular diet (regular bread and regular drinking yoghurt; n=17)
Number of subjects: 34
Study 23447519 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholic acid (CA) 15 mg/kg per day
Number of subjects: 18
Study 23447519 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 21374656 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFN/ribavirin therapy
Number of subjects: 281
Study 19919189 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine (TM)
Number of subjects: 221
Study 17024948 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional GIC (Ketac-Fil Plus Aplicap) on sound dentin
Number of subjects: 4
Study 17024948 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional GIC (Ketac-Fil Plus Aplicap) on artificially created carious dentin
Number of subjects: 4
Study 17024948 — intervention group
Group type: EXPERIMENTAL
Intervention: RMGIC (Photac-Fil Aplicap) on sound dentin
Number of subjects: 4
Study 17024948 — intervention group
Group type: EXPERIMENTAL
Intervention: RMGIC (Photac-Fil Aplicap) on artificially created carious dentin
Number of subjects: 4
Study 12492800 — intervention group
Group type: EXPERIMENTAL
Intervention: HES 450/0.7/4.6
Number of subjects: 50
Study 12492800 — intervention group
Group type: EXPERIMENTAL
Intervention: HES 70/0.5/4
Number of subjects: 50
Study 12492800 — intervention group
Group type: EXPERIMENTAL
Intervention: HES 200/0.6/9.4
Number of subjects: 50
Study 12492800 — intervention group
Group type: EXPERIMENTAL
Intervention: HES 130/0.4/9
Number of subjects: 50
Study 12492800 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 50
Study 11103114 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg of urapidil (group U, n = 22)
Number of subjects: 44
Study 11103114 — intervention group
Group type: COMPARATOR
Intervention: Nothing (group N, n = 22)
Number of subjects: 44
Study 11103114 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg of urapidil (group U)
Number of subjects: 44
Study 11103114 — intervention group
Group type: COMPARATOR
Intervention: Nothing (group N)
Number of subjects: 44
Study 9179227 — intervention group
Group type: EXPERIMENTAL
Intervention: 90Y/111In-DOTA-peptide-ChL6
Number of subjects: 3
Study 9179227 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic doses of 90Y-DOTA-peptide-ChL6
Number of subjects: 3
Study 9179227 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracer doses of 111In-DOTA-peptide-ChL6
Number of subjects: 3
Study 9179227 — intervention group
Group type: COMPARATOR
Intervention: 90Y-DOTA-peptide-ChL6
Number of subjects: 3
Study 1489548 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of paroxetine, a serotonin re-uptake inhibitor
Number of subjects: 7
Study 1489548 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 2857117 — intervention group
Group type: COMPARATOR
Intervention: Nizatidine 6.25, 25, 75, 150, or 250 mg (single 20-min intravenous infusion)
Number of subjects: 15
Study 2857117 — intervention group
Group type: COMPARATOR
Intervention: Nizatidine 25, 50, 100, or 250 mg (5-min intravenous infusion weekly for 6 weeks)
Number of subjects: 15
Study 2857117 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine 300 mg (5-min intravenous infusion weekly for 6 weeks)
Number of subjects: 15
Study 2857117 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5-min intravenous infusion weekly for 6 weeks)
Number of subjects: 15
Study 29410180 — intervention group
Group type: EXPERIMENTAL
Intervention: Plerixafor plus 10 µg/kg G-CSF
Number of subjects: 330
Study 29410180 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus 10 µg/kg G-CSF
Number of subjects: 330
Study 26773784 — intervention group
Group type: EXPERIMENTAL
Intervention: Almonds (1.5 oz for parents, 0.5 oz for children)
Number of subjects: 58
Study 26773784 — intervention group
Group type: COMPARATOR
Intervention: Control (no almonds)
Number of subjects: 58
Study 26773784 — intervention group
Group type: EXPERIMENTAL
Intervention: Almonds
Number of subjects: 58
Study 24523007 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)‐based counseling intervention called Uphungu Wanga
Number of subjects: 0
Study 24523007 — intervention group
Group type: COMPARATOR
Intervention: Brief education sessions about HIV and AHI
Number of subjects: 0
Study 21977812 — intervention group
Group type: EXPERIMENTAL
Intervention: Busui Shengxue Granule
Number of subjects: 65
Study 21977812 — intervention group
Group type: COMPARATOR
Intervention: Zaizhang Shengxue Tablet
Number of subjects: 65
Study 19214129 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft contact lenses
Number of subjects: 484
Study 19214129 — intervention group
Group type: COMPARATOR
Intervention: Spectacles
Number of subjects: 484
Study 16472855 — intervention group
Group type: EXPERIMENTAL
Intervention: In-office bleaching with 38% hydrogen peroxide for 15, 30, and 45 minutes
Number of subjects: 84
Study 16472855 — intervention group
Group type: COMPARATOR
Intervention: Control group (unbleached samples)
Number of subjects: 84
Study 15791379 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenyö-Lindberg scoring system
Number of subjects: 455
Study 11309012 — intervention group
Group type: EXPERIMENTAL
Intervention: B‐IINB (ilioinguinal and iliohypogastric nerve block) with 10 ml of 0.5% bupivacaine
Number of subjects: 100
Study 11309012 — intervention group
Group type: COMPARATOR
Intervention: S‐IINB (saline control)
Number of subjects: 100
Study 11309012 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (B‐IINB and S‐IINB)
Number of subjects: 100
Study 9154850 — intervention group
Group type: EXPERIMENTAL
Intervention: Education and action plan based on peak-flow monitoring (Group P)
Number of subjects: 188
Study 9154850 — intervention group
Group type: EXPERIMENTAL
Intervention: Education with action plan based on monitoring of asthma symptoms (Group S)
Number of subjects: 188
Study 9154850 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 188
Study 9154850 — intervention group
Group type: EXPERIMENTAL
Intervention: Education and action plan based on peak-flow monitoring (Group P) and Education with action plan based on monitoring of asthma symptoms (Group S)
Number of subjects: 188
Study 8102665 — intervention group
Group type: EXPERIMENTAL
Intervention: Habitual sports and exercise activities (experimental group)
Number of subjects: 400
Study 8102665 — intervention group
Group type: COMPARATOR
Intervention: Advised not to play 'risky' sports (control group)
Number of subjects: 400
Study 8102665 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with normal atlantoaxial distances (third group)
Number of subjects: 400
Study 3311954 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg b.i.d.
Number of subjects: 117
Study 3311954 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg nocte
Number of subjects: 117
Study 359083 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral neomycin and metronidazole added to bowel preparation
Number of subjects: 120
Study 359083 — intervention group
Group type: COMPARATOR
Intervention: Standard mechanical preparation
Number of subjects: 120
Study 359083 — intervention group
Group type: COMPARATOR
Intervention: Elemental diet
Number of subjects: 120
Study 30099769 — intervention group
Group type: EXPERIMENTAL
Intervention: HaemoCer™ (absorbable polysaccharide hemostatic powder)
Number of subjects: 155
Study 28557585 — intervention group
Group type: EXPERIMENTAL
Intervention: IMRT and concurrent 5-FU/MMC
Number of subjects: 26
Study 25766094 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical CPR
Number of subjects: 206
Study 25766094 — intervention group
Group type: COMPARATOR
Intervention: Manual CPR
Number of subjects: 206
Study 23357614 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated information display
Number of subjects: 12
Study 23357614 — intervention group
Group type: COMPARATOR
Intervention: Traditional displays
Number of subjects: 12
Study 21412803 — intervention group
Group type: EXPERIMENTAL
Intervention: IAA PDT
Number of subjects: 14
Study 19586142 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic alliance intervention (TA) added to usual treatment
Number of subjects: 632
Study 19586142 — intervention group
Group type: EXPERIMENTAL
Intervention: 2‐session, counseling and education, HIV/HCV risk reduction intervention (C&E) added to usual treatment
Number of subjects: 632
Study 19586142 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU) only
Number of subjects: 632
Study 17542057 — intervention group
Group type: COMPARATOR
Intervention: Standard 30-min infusion of gemcitabine (1200 mg/m(2))
Number of subjects: 12
Study 17542057 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed dose rate (FDR) infusion of gemcitabine (10 mg/(m(2) x min))
Number of subjects: 12
Study 15482353 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan 100 mg tablets (early treatment)
Number of subjects: 0
Study 15482353 — intervention group
Group type: COMPARATOR
Intervention: Sumatriptan 100 mg tablets (late treatment)
Number of subjects: 0
Study 11574356 — intervention group
Group type: EXPERIMENTAL
Intervention: Music during the perioperative period (Group I)
Number of subjects: 50
Study 11574356 — intervention group
Group type: COMPARATOR
Intervention: No music (Group II)
Number of subjects: 50